Cargando…
In Vivo Antitumor Activity of a Novel Acetazolamide–Cryptophycin Conjugate for the Treatment of Renal Cell Carcinomas
[Image: see text] Traditional chemotherapeutics used in cancer therapy do not preferentially accumulate in tumor tissues. The conjugation to delivery vehicles like antibodies or small molecules has been proposed as a strategy to increase the tumor uptake and improve the therapeutic window of these d...
Autores principales: | Cazzamalli, Samuele, Figueras, Eduard, Pethő, Lilla, Borbély, Adina, Steinkühler, Christian, Neri, Dario, Sewald, Norbert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2018
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276201/ https://www.ncbi.nlm.nih.gov/pubmed/30533574 http://dx.doi.org/10.1021/acsomega.8b02350 |
Ejemplares similares
-
In Vivo Antitumor Activity of a Novel Acetazolamide–Cryptophycin
Conjugate for the Treatment of Renal Cell Carcinoma
por: Cazzamalli, Samuele, et al.
Publicado: (2018) -
Linker Hydrophilicity Modulates the Anticancer Activity of RGD–Cryptophycin Conjugates
por: Anselmi, Michele, et al.
Publicado: (2020) -
Synthesis and Biological Characterization of Monomeric and Tetrameric RGD‐Cryptophycin Conjugates
por: Borbély, Adina, et al.
Publicado: (2020) -
Conjugates of Cryptophycin and RGD or isoDGR Peptidomimetics for Targeted Drug Delivery
por: Borbély, Adina, et al.
Publicado: (2019) -
Synthesis and Biological Evaluation of RGD–Cryptophycin Conjugates for Targeted Drug Delivery
por: Borbély, Adina, et al.
Publicado: (2019)